who should not take glp-1 receptor agonists Independent Nurse - and GIP/GLP-1 for type 2 diabetes Frontiers | GLP-1 Receptor Agonists:
Description
For some, its a mild queasiness
In contrast, the pharmacological nanomolar concentrations of GLP-1RAs predominantly activate the cAMP/PKA pathway, potentially explaining their broader therapeutic effects [122]
Some GLP-1 agonists have demonstrated cardiovascular risk reduction in clinical trials
But then look at the GLP-1 data
J Diabetes Res 2019(9426014)
